<?xml version="1.0" ?>
<document id="46c2eb2186aa09c3963227ce0195a881ac26de7d">
  <chunk id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c0" text="Cell-Penetrating Peptides for Antiviral Drug Development">
    <entity charOffset="17-25" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c0.e0" ontology_id="CHEBI_16670" text="Peptides" type="chemical"/>
    <entity charOffset="30-39" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c0.e1" ontology_id="CHEBI_22587" text="Antiviral" type="chemical"/>
    <entity charOffset="30-44" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c0.e2" ontology_id="CHEBI_36044" text="Antiviral Drug" type="chemical"/>
    <entity charOffset="40-44" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c0.e3" ontology_id="CHEBI_23888" text="Drug" type="chemical"/>
  </chunk>
  <chunk id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1" text="Viral diseases affect hundreds of millions of people worldwide, and the few available drugs to treat these diseases often come with limitations. The key obstacle to the development of new antiviral agents is their delivery into infected cells in vi vo. Cell-penetrating peptides (CPPs) are short peptides that can cross the cellular lipid bilayer with the remarkable capability to shuttle conjugated cargoes into cells. CPPs have been successfully utilized to enhance the cellular uptake and intracellular trafficking of antiviral molecules, and thereby increase the inhibitory activity of potential antiviral proteins and oligonucleotide analogues, both in cultured cells and in animal models. This review will address the notable findings of these studies, highlighting some promising results and discussing the challenges CPP technology has to overcome for further clinical applications.">
    <entity charOffset="86-91" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e0" ontology_id="CHEBI_23888" text="drugs" type="chemical"/>
    <entity charOffset="188-197" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="188-204" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e2" ontology_id="CHEBI_22587" text="antiviral agents" type="chemical"/>
    <entity charOffset="270-278" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e3" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="296-304" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e4" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="333-338" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e5" ontology_id="CHEBI_18059" text="lipid" type="chemical"/>
    <entity charOffset="521-530" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e6" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="600-609" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e7" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="610-618" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e8" ontology_id="CHEBI_36080" text="proteins" type="chemical"/>
    <entity charOffset="623-638" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e9" ontology_id="CHEBI_7754" text="oligonucleotide" type="chemical"/>
    <entity charOffset="825-828" id="46c2eb2186aa09c3963227ce0195a881ac26de7d.c1.e10" ontology_id="CHEBI_34603" text="CPP" type="chemical"/>
  </chunk>
</document>
